Payment overview · 2025
General Payments
$2,566.00
99 reported records · 28 companies
Healthcare provider profile · identity verified
Shovek Boyadjian
Allopathic & Osteopathic Physicians|Family Medicine · PANORAMA CITY, CA · NPI 1619950342
Verified facts
What the public records show
CMS Open Payments records show Shovek Boyadjian received $2,566.00 in general payments during 2025 across 99 reported records.
Ardelyx, Inc. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Creon, Entresto, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Prolia, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Trulance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 461 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nexium by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Auvelity by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 482 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $361.63 | 14.1% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $332.97 | 13.0% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $278.67 | 10.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $254.39 | 9.9% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $118.17 | 4.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.47 | 4.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $101.16 | 3.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.92 | 3.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.25 | 3.5% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $74.08 | 2.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.10 | 2.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.38 | 2.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.27 | 2.6% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $64.54 | 2.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.63 | 2.4% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $61.04 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.80 | 1.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.87 | 1.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38.48 | 1.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.35 | 1.5% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.61 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.92 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.88 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.42 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.39 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.07 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.96 | 0.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.58 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,566.00 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $361.63 | 13 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $235.25 | 10 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $202.75 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $169.90 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $165.03 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $147.62 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $140.87 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $118.17 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.77 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $101.16 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.92 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.92 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $80.62 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $74.08 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $72.72 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $71.10 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $67.38 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.27 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.27 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $64.54 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.63 | 2 | 2025 |
Source payment records
|
|||||
| INSIGNIA Normalized: insignia |
Device | Stryker Corporation | $61.04 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $57.08 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $54.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $37.35 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $29.88 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 140 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 227 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 137 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 356 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 117 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 461 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 130 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 213 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 62 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 185 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 229 | exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
140 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
461 | 73 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
62 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
117 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
356 | 42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
185 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
356 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
170 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
227 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
213 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
482 | 61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
229 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 2045 | 238 |
| Gabapentin | Gabapentin | 1374 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1070 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1068 | 125 |
| Omeprazole | Omeprazole | 966 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 918 | 136 |
| Metoprolol Tartrate | Metoprolol Tartrate | 874 | 114 |
| Metformin Hcl | Metformin Hcl | 841 | 95 |
| Furosemide | Furosemide | 737 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 109 |
| Escitalopram Oxalate | Escitalopram Oxalate | 725 | 90 |
| Allopurinol | Allopurinol | 704 | 85 |
| Donepezil Hcl | Donepezil Hcl | 666 | 78 |
| Clonidine Hcl | Clonidine Hcl | 648 | 90 |
| Losartan Potassium | Losartan Potassium | 570 | 72 |
| Ibuprofen | Ibuprofen | 569 | 101 |
| Hydralazine Hcl | Hydralazine Hcl | 550 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 524 | 62 |
| Benazepril Hcl | Benazepril Hcl | 494 | 58 |
| Eliquis | Apixaban | 482 | 61 |
| Meclizine Hcl | Meclizine Hcl | 469 | 64 |
| Linzess | Linaclotide | 461 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 442 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 407 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 395 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 383 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 377 | 44 |
| Meloxicam | Meloxicam | 373 | 54 |
| Jardiance | Empagliflozin | 356 | 42 |
| Lisinopril | Lisinopril | 338 | 40 |
| Januvia | Sitagliptin Phosphate | 327 | 43 |
| Celecoxib | Celecoxib | 316 | 39 |
| Gemfibrozil | Gemfibrozil | 309 | 43 |
| Vascepa | Icosapent Ethyl | 303 | 37 |
| Potassium Chloride | Potassium Chloride | 292 | 47 |
| Carvedilol | Carvedilol | 276 | 40 |
| Montelukast Sodium | Montelukast Sodium | 271 | 33 |
| Repatha Sureclick | Evolocumab | 263 | 37 |
| Mirtazapine | Mirtazapine | 260 | 42 |
| Glipizide | Glipizide | 244 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 242 | 43 |
| Azithromycin | Azithromycin | 240 | 177 |
| Simvastatin | Simvastatin | 238 | 29 |
| Dexlansoprazole Dr | Dexlansoprazole | 230 | 31 |
| Trintellix | Vortioxetine Hydrobromide | 229 | 32 |
| Entresto | Sacubitril/Valsartan | 227 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 42 |
| Icosapent Ethyl | Icosapent Ethyl | 214 | 42 |
| Lorazepam | Lorazepam | 214 | 48 |
| Olanzapine | Olanzapine | 214 | 23 |
| Ozempic | Semaglutide | 213 | 31 |
| Metoclopramide Hcl | Metoclopramide Hcl | 212 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 207 | 32 |
| Hydrocortisone | Hydrocortisone | 197 | 30 |
| Atenolol | Atenolol | 191 | 21 |
| Tramadol Hcl | Tramadol Hcl | 190 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 23 |
| Famotidine | Famotidine | 189 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 185 | 30 |
| Alendronate Sodium | Alendronate Sodium | 184 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 184 | 25 |
| Ibu | Ibuprofen | 183 | 39 |
| Sertraline Hcl | Sertraline Hcl | 181 | 20 |
| Myrbetriq | Mirabegron | 180 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 176 | 20 |
| Baclofen | Baclofen | 175 | 25 |
| Trulicity | Dulaglutide | 170 | 21 |
| Trazodone Hcl | Trazodone Hcl | 167 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 163 | 20 |
| Metformin Er Gastric | Metformin Hcl | 152 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 149 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 147 | 18 |
| Ezetimibe | Ezetimibe | 147 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 143 | 12 |
| Tradjenta | Linagliptin | 141 | 11 |
| Creon | Lipase/Protease/Amylase | 140 | 25 |
| Levetiracetam | Levetiracetam | 139 | 15 |
| Farxiga | Dapagliflozin Propanediol | 137 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 137 | 18 |
| Finasteride | Finasteride | 134 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 132 | 22 |
| Mounjaro | Tirzepatide | 130 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 126 | 17 |
| Alprazolam | Alprazolam | 119 | 26 |
| Kerendia | Finerenone | 117 | 20 |
| Buspirone Hcl | Buspirone Hcl | 115 | 14 |
| Naproxen | Naproxen | 114 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 114 | 12 |
| Divalproex Sodium | Divalproex Sodium | 111 | 13 |
| Memantine Hcl Er | Memantine Hcl | 111 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 111 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 111 | 22 |
| Lidocaine | Lidocaine | 105 | 19 |
| Spironolactone | Spironolactone | 101 | 13 |
| Risperidone | Risperidone | 99 | suppressed |
| Valsartan | Valsartan | 99 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 98 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 94 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 92 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 89 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 89 | 11 |
| Latanoprost | Latanoprost | 89 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 89 | 17 |
| Glipizide Er | Glipizide | 88 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | suppressed |
| Nitroglycerin | Nitroglycerin | 83 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 81 | suppressed |
| Glimepiride | Glimepiride | 79 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 79 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 79 | 15 |
| Colchicine | Colchicine | 75 | suppressed |
| Memantine Hcl | Memantine Hcl | 75 | 11 |
| Ketoconazole | Ketoconazole | 74 | 12 |
| Prednisone | Prednisone | 73 | 17 |
| Ranolazine Er | Ranolazine | 72 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 67 | suppressed |
| Rybelsus | Semaglutide | 67 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 65 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 65 | suppressed |
| Clonazepam | Clonazepam | 63 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 54 |
| Clotrimazole | Clotrimazole | 62 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 62 | suppressed |
| Prolia | Denosumab | 62 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 54 |
| Bumetanide | Bumetanide | 60 | 11 |
| Digoxin | Digoxin | 59 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | suppressed |
| Novolog Flexpen | Insulin Aspart | 58 | 13 |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 54 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 54 | 30 |
| Praluent Pen | Alirocumab | 54 | 12 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 53 | suppressed |
| Permethrin | Permethrin | 52 | 38 |
| Trulance | Plecanatide | 52 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 51 | 19 |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Methimazole | Methimazole | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | suppressed |
| Telmisartan | Telmisartan | 49 | suppressed |
| Carbamazepine | Carbamazepine | 48 | suppressed |
| Febuxostat | Febuxostat | 48 | suppressed |
| Lubiprostone | Lubiprostone | 48 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 47 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 46 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 43 | suppressed |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | 38 |
| Restasis | Cyclosporine | 42 | suppressed |
| Tavaborole | Tavaborole | 42 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Amantadine | Amantadine Hcl | 40 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 14 |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 29 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Cilostazol | Cilostazol | 37 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 37 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 37 | suppressed |
| Nystatin | Nystatin | 37 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Clonidine | Clonidine | 35 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 35 | 17 |
| Repatha Pushtronex | Evolocumab | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Mirabegron Er | Mirabegron | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 21 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 24 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 29 | 12 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 28 | suppressed |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Alogliptin | Alogliptin Benzoate | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | 12 |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Primidone | Primidone | 25 | suppressed |
| Repatha Syringe | Evolocumab | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 24 | 14 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Ivermectin | Ivermectin | 20 | 18 |
| Nexium | Esomeprazole Magnesium | 20 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Dexilant | Dexlansoprazole | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Cyclosporine | Cyclosporine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 18 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Paliperidone Er | Paliperidone | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Brilinta | Ticagrelor | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 15 |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Clozapine | Clozapine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Loxapine | Loxapine Succinate | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,566.00 · 99 records | Ardelyx, Inc. | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CREON, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INSIGNIA, JARDIANCE, Kerendia, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TRULANCE, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error